ACRS Aclaris Therapeutics Potential Buyout

ACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025.

ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023.

ACRS reached 52 week low today: $5.05.

Analysts Price Targets:
$21 The Goldman Sachs Group
$29 BTIG Research
$38 Cantor Fitzgerald
$43 HC Wainwright

Considering the above, I think ACRS might be an easy +3X!

Looking forward to read your opinion about it.